Harmony Biosciences (HRMY)


Market Price (11/18/2026): $33.025 | Market Cap: $1.9 BilSector: Health Care | Industry: Biotechnology

Harmony Biosciences (HRMY)


Market Price (11/18/2026): $33.025
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.2%, FCF Yield is 17%

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -32%

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 22%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 33%

Low stock price volatility
Vol 12M is 41%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies.

Weak multi-year price returns
2Y Excs Rtn is -30%, 3Y Excs Rtn is -29%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%

Key risks
HRMY key risks include [1] its substantial dependence on a single product, Show more.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.2%, FCF Yield is 17%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -32%
2 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 22%
3 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 33%
4 Low stock price volatility
Vol 12M is 41%
5 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies.
6 Weak multi-year price returns
2Y Excs Rtn is -30%, 3Y Excs Rtn is -29%
7 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
8 Key risks
HRMY key risks include [1] its substantial dependence on a single product, Show more.

HRMY in ETFs

Weight = HRMY's share of each fund

VTI0.00%
ITOT0.00%
IWM0.05%
IJR0.10%
VB0.02%
AVUV0.30%
SLYG0.20%
IJT0.20%
+10 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 5: down 5.7% in one day (S&P 500 down 4.4%)
The stock declined as the broader market fell, driven by concerns about AI stocks. Company Q3 earnings also missed estimates due to higher costs despite Wakix growth.

Down 24.2% from its Sep 2 high to Nov 5 (S&P 500 down 4.0%)
The stock experienced a significant decline, largely driven by its Q3 earnings reporting lower than expected results. Its largest drops occurred on October 22, and November 4 and November 5 following disappointing Q3 earnings.

Nov 4: down 7.0% on its earnings report (S&P 500 up 1.7%)
The stock fell after reporting Q3 earnings and revenues that lagged analyst estimates. Diluted EPS was $0.81, missing the consensus, while net income declined year-over-year.

Show more
Prices as of 11/17/2026

Nov 5: down 5.7% in one day (S&P 500 down 4.4%)
The stock declined as the broader market fell, driven by concerns about AI stocks. Company Q3 earnings also missed estimates due to higher costs despite Wakix growth.

Down 24.2% from its Sep 2 high to Nov 5 (S&P 500 down 4.0%)
The stock experienced a significant decline, largely driven by its Q3 earnings reporting lower than expected results. Its largest drops occurred on October 22, and November 4 and November 5 following disappointing Q3 earnings.

Nov 4: down 7.0% on its earnings report (S&P 500 up 1.7%)
The stock fell after reporting Q3 earnings and revenues that lagged analyst estimates. Diluted EPS was $0.81, missing the consensus, while net income declined year-over-year.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -6.3% change in HRMY stock from 7/31/2026 to 11/17/2026 was primarily driven by a -22.8% change in the company's P/E Multiple.
(LTM values as of)731202611172026Change
Stock Price ($)35.2433.01-6.3%
Change Contribution By: 
Total Revenues ($ Mil)89998910.0%
Net Income Margin (%)16.2%18.1%11.5%
P/E Multiple14.010.8-22.8%
Shares Outstanding (Mil)5858-1.0%
Cumulative Contribution-6.3%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
HRMY-6.3% 
Market (SPY)-1.7%35.4%
Sector (XLV)14.4%19.7%

Fundamental Drivers

The 5.6% change in HRMY stock from 4/30/2026 to 11/17/2026 was primarily driven by a 13.9% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611172026Change
Stock Price ($)31.2633.015.6%
Change Contribution By: 
Total Revenues ($ Mil)86898913.9%
Net Income Margin (%)18.3%18.1%-1.2%
P/E Multiple11.210.8-3.9%
Shares Outstanding (Mil)5758-2.4%
Cumulative Contribution5.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
HRMY5.6% 
Market (SPY)2.4%18.4%
Sector (XLV)27.9%24.4%

Fundamental Drivers

The 15.5% change in HRMY stock from 10/31/2025 to 11/17/2026 was primarily driven by a 28.1% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511172026Change
Stock Price ($)28.5733.0115.5%
Change Contribution By: 
Total Revenues ($ Mil)77398928.1%
Net Income Margin (%)23.4%18.1%-22.9%
P/E Multiple9.110.818.9%
Shares Outstanding (Mil)5758-1.6%
Cumulative Contribution15.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
HRMY15.5% 
Market (SPY)8.5%20.0%
Sector (XLV)30.6%22.6%

Fundamental Drivers

The 40.2% change in HRMY stock from 10/31/2023 to 11/17/2026 was primarily driven by a 82.6% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311172026Change
Stock Price ($)23.5433.0140.2%
Change Contribution By: 
Total Revenues ($ Mil)54298982.6%
Net Income Margin (%)27.8%18.1%-35.1%
P/E Multiple9.310.815.5%
Shares Outstanding (Mil)60582.5%
Cumulative Contribution40.2%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
HRMY40.2% 
Market (SPY)81.6%25.0%
Sector (XLV)56.4%24.8%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HRMY Return18%29%-41%7%9%-12%-9%
Peers Return-25%30%20%-6%40%13%74%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
HRMY Win Rate42%58%50%58%58%36% 
Peers Win Rate52%58%52%47%60%47% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
HRMY Max Drawdown-36%-36%-65%-23%-36%-31% 
Peers Max Drawdown-50%-37%-32%-34%-33%-35% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: JAZZ, AXSM, ALKS, NBIX, ACAD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventHRMYS&P 500
2025 US Tariff Shock
  % Loss-20.9%-18.8%
  % Gain to Breakeven26.4%23.1%
  Time to Breakeven26 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.3%-9.5%
  % Gain to Breakeven89.8%10.5%
  Time to Breakeven299 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-26.0%-24.5%
  % Gain to Breakeven35.2%32.4%
  Time to Breakeven42 days427 days

Compare to JAZZ, AXSM, ALKS, NBIX, ACAD

In The Past

Harmony Biosciences's stock fell -20.9% during the 2025 US Tariff Shock. Such a loss loss requires a 26.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventHRMYS&P 500
2025 US Tariff Shock
  % Loss-20.9%-18.8%
  % Gain to Breakeven26.4%23.1%
  Time to Breakeven26 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.3%-9.5%
  % Gain to Breakeven89.8%10.5%
  Time to Breakeven299 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-26.0%-24.5%
  % Gain to Breakeven35.2%32.4%
  Time to Breakeven42 days427 days

Compare to JAZZ, AXSM, ALKS, NBIX, ACAD

In The Past

Harmony Biosciences's stock fell -20.9% during the 2025 US Tariff Shock. Such a loss loss requires a 26.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Harmony Biosciences (HRMY)

```html

Harmony Biosciences (HRMY) is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders in the United States. The company, incorporated in 2017 and based in Plymouth Meeting, Pennsylvania, aims to address specific medical needs within this specialized therapeutic area.

The company's primary product is WAKIX (pitolisant), a medication specifically approved for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Harmony Biosciences' main customers are adult patients in the U.S. diagnosed with narcolepsy who experience this particular symptom, positioning the company as a key provider of treatments for this rare neurological condition.

```

AI Analysis | Feedback

Harmony Biosciences (HRMY) can be described as:

  • Jazz Pharmaceuticals, but primarily focused on its narcolepsy drug WAKIX.
  • Vertex Pharmaceuticals, but for rare neurological sleep disorders.

AI Analysis | Feedback

  • WAKIX: A medication used for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

AI Analysis | Feedback

Harmony Biosciences (HRMY), as a commercial-stage pharmaceutical company, sells its medication WAKIX through the established pharmaceutical distribution channels in the United States. Therefore, its major customers are typically large pharmaceutical wholesalers and distributors, who then supply pharmacies and healthcare providers.

The major customers of Harmony Biosciences are most likely the major pharmaceutical wholesalers in the United States. These include:

  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)

These companies purchase medications in bulk from manufacturers like Harmony Biosciences and distribute them to retail pharmacies, hospital pharmacies, and other healthcare facilities across the country, which then dispense the medication to individual patients based on prescriptions.

AI Analysis | Feedback

  • Flamma S.p.A.
  • Alcami Corporation

AI Analysis | Feedback

Jeffrey M. Dayno, President and Chief Executive Officer

Dr. Jeffrey M. Dayno assumed the role of President and Chief Executive Officer of Harmony Biosciences in April 2023, having previously served as Interim CEO from January to April 2023. He initially joined Harmony Biosciences as Chief Medical Officer and Executive Vice President in November 2017, the year the company was founded. With over 25 years of experience in the pharmaceutical industry and a background as a practicing neurologist, Dr. Dayno has held leadership positions at various pharmaceutical companies, including Merck & Co., Cephalon, Egalet Corporation (Zyla Life Sciences), and ViroPharma (which was acquired by Shire). He has been instrumental in multiple NDA approvals and product launches throughout his career, and at Harmony, he played a critical role in the FDA approval of WAKIX. Dr. Dayno currently serves on the board of Emalex Biosciences and previously served on the board of Atrin Pharmaceuticals.

Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer

Sandip Kapadia was appointed Chief Financial Officer of Harmony Biosciences effective March 29, 2021. He possesses over 25 years of experience in the life sciences industry, offering strategic financial oversight to companies in both the United States and Europe. Before joining Harmony Biosciences, Mr. Kapadia served as the Chief Financial Officer at Intercept, where he was responsible for leading finance operations, supporting commercialization efforts, executing financial and capital strategies, and raising over $700 million in various financings. Prior to Intercept, he spent a significant portion of his career at Novartis and its affiliates, including serving as Chief Financial Officer of North America at Sandoz, Novartis's generic division. Mr. Kapadia is a Certified Public Accountant and holds an MBA from Rutgers University and a BBA from Montclair State University. He is also a board member of Passage Bio, Inc., Molecular Partners AG, and VectivBio Holding AG.

Dr. Kumar Budur, Executive Vice President, Chief Medical and Scientific Officer

Dr. Kumar Budur serves as the Executive Vice President, Chief Medical and Scientific Officer at Harmony Biosciences, playing a key role in the company's research, development, and medical affairs.

Andrew Serafin, Chief Strategy Officer

Andrew Serafin holds the position of Chief Strategy Officer at Harmony Biosciences, contributing to the company's strategic planning and initiatives.

Adam Zaeske, Chief Commercial Officer

Adam Zaeske is the Chief Commercial Officer at Harmony Biosciences, overseeing the company's commercial operations and strategies.

AI Analysis | Feedback

Here are the key risks to Harmony Biosciences:
  1. Patent Litigation and Potential for Early Generic Competition for WAKIX: Harmony Biosciences faces significant risk from ongoing intellectual property litigation concerning its primary drug, WAKIX. Analysts have downgraded the company's stock due to concerns about a potential unfavorable ruling in an intellectual property case, which could allow generic versions of WAKIX to enter the market much earlier than anticipated, possibly as soon as this year instead of 2030. This would severely impact Harmony's main revenue source.
  2. High Reliance on a Single Commercial Product (WAKIX) and Pipeline Development Challenges: The company is heavily reliant on WAKIX for its revenue, making it vulnerable to any issues affecting this product. Harmony's efforts to diversify its product portfolio have faced setbacks, including the failure of a key pipeline candidate, ZYN-002, in its Phase 3 RECONNECT trial for Fragile X Syndrome. Such pipeline failures increase the company's dependence on WAKIX and limit future growth prospects.
  3. Competitive Market and Drug Pricing Pressures: While WAKIX offers a unique mechanism of action, it operates in a competitive market for narcolepsy treatments. Additionally, Harmony Biosciences, like other pharmaceutical companies, is subject to pressures on US drug prices, which could negatively impact the profitability and market position of WAKIX.

AI Analysis | Feedback

Competition from Avadel Pharmaceuticals' Lumryz, an extended-release sodium oxybate product for narcolepsy approved by the FDA in May 2023. Its once-nightly dosing offers a potential convenience advantage over existing treatments, increasing competition in the narcolepsy market.
The ongoing development of novel orexin receptor agonists by various pharmaceutical companies. These drugs, while some specific programs have faced setbacks, aim to address the underlying pathology of narcolepsy type 1 and could offer more effective or disease-modifying treatments than symptomatic therapies like WAKIX if successfully brought to market.

AI Analysis | Feedback

Harmony Biosciences' main product, WAKIX, addresses the market of patients diagnosed with narcolepsy in the United States.

The addressable market for WAKIX in the U.S. is estimated to be approximately 80,000 diagnosed patients with narcolepsy. Harmony Biosciences has stated that this represents a "large market opportunity" for WAKIX.

The company is guiding WAKIX net revenue to exceed $1 billion, reaching between $1 billion and $1.04 billion, in 2026, indicating this as their targeted opportunity within the narcolepsy market. The overall narcolepsy therapeutics market in the United States was approximately $1.19 billion in 2023 and is projected to reach $1.87 billion by 2030.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Harmony Biosciences (HRMY)

Over the next 2-3 years, Harmony Biosciences (HRMY) is expected to drive future revenue growth through several key initiatives, primarily centered around its flagship product WAKIX and a robust pipeline expansion:

  1. Continued Growth and Patient Adoption of WAKIX in Narcolepsy: Harmony Biosciences anticipates sustained revenue growth from its commercial-stage product, WAKIX, for excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company has consistently reported strong demand for WAKIX, with an increase in average patients, and has provided guidance for WAKIX net revenue to reach blockbuster status of $1 billion to $1.04 billion in 2026. This growth is driven by WAKIX's broad clinical utility and ongoing commercial execution.
  2. Expansion of WAKIX Label into New Indications and Patient Populations: Harmony Biosciences is pursuing label expansions for WAKIX to address a broader patient base. A significant driver is the recent FDA approval of WAKIX for the treatment of cataplexy in pediatric narcolepsy patients aged six years and older, which supports pediatric exclusivity and market expansion. Additionally, the company is evaluating pitolisant (WAKIX's active ingredient) for other neurological disorders, including a planned sNDA submission for idiopathic hypersomnia and ongoing Phase 3 trials for pitolisant in Prader-Willi syndrome with topline data expected in the second half of 2026.
  3. Launch of Next-Generation Pitolisant Formulations: The company is advancing new formulations of pitolisant, including Pitolisant GR (gastro-resistant) and Pitolisant HD (high dose). An NDA submission for Pitolisant GR is on track for Q2 2026, with a target PDUFA date in Q1 2027. Pitolisant HD is currently in Phase 3 registrational clinical trials for narcolepsy (ONSTRIDE 1) and idiopathic hypersomnia (ONSTRIDE 2), with topline data anticipated in 2027 and potential PDUFA dates in 2028. These next-gen formulations are designed to enhance patient adherence and efficacy, extending the pitolisant franchise into the 2040s and expanding its utility for differentiated indications like fatigue in narcolepsy and sleep inertia in idiopathic hypersomnia.
  4. Advancement and Potential Commercialization of Late-Stage Pipeline Assets: Harmony Biosciences has a robust late-stage pipeline beyond pitolisant, with five ongoing Phase 3 registrational clinical trials across five distinct CNS indications. This includes BP1.15205, a potential best-in-class Orexin-2 agonist, which is currently in a Phase 1 trial with clinical data expected in mid-2026. The company is making strategic investments in research and development to advance these pipeline assets, which are expected to diversify revenue streams beyond WAKIX and contribute to long-term value creation.

AI Analysis | Feedback

Share Repurchases

  • Harmony Biosciences' Board of Directors authorized a $200 million equity buyback program on October 31, 2023.
  • Prior to this, a $125 million share repurchase program was announced on August 1, 2023, reflecting confidence in the company's financial health and growth potential.
  • As of March 31, 2025, the company had repurchased 1,814,653 shares for approximately $49.99 million under the October 31, 2023 buyback plan.

Share Issuance

  • On October 29, 2024, an underwritten public offering of up to 8,000,000 shares of Harmony Biosciences' common stock was commenced by selling shareholders (Marshman Fund Trust II and Valor IV Pharma Holdings, LLC). The company itself did not offer any shares and received no proceeds from this offering.

Inbound Investments

  • Zuckerman Investment Group LLC acquired a new stake of 123,255 shares in Harmony Biosciences, valued at approximately $3.40 million, during the third quarter (prior to March 2026).
  • Institutional investors and hedge funds collectively own approximately 86.23% of the company's stock.

Outbound Investments

  • Harmony Biosciences' strategy includes deploying capital for business development to expand its pipeline and commercial portfolio.
  • In Q2 2025, operating expenses included $42.6 million in in-process research and development (IPR&D) charges from Q2 2024 related to a sublicensing agreement with Bioprojet for an orexin-2 agonist compound and the acquisition of Epygenix.
  • This was partially offset by a $15.0 million IPR&D charge for an upfront fee from the 2025 CiRC Agreement.

Capital Expenditures

  • Harmony Biosciences' capital expenditures have been consistently low, with $0.17 million in 2025, $0.30 million in 2024, $0.00 million in 2023, and $0.15 million in 2022.
  • In Q4 2025, the company invested $107K in capital expenditures, primarily funding long-term assets and infrastructure.
  • The company's overall investment focus includes advancing its late-stage pipeline and supporting the commercialization of WAKIX.

Better Bets vs. Harmony Biosciences (HRMY)

Peer Outperformance in Biotechnology

HRMY has outperformed 75% of its 369 Biotechnology peers over 5Y. Among the peers that beat it are INCY, LGND and VCEL. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that HRMY has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
66%
of 453 industry peers · -2.9% return
3Y
68%
of 399 industry peers · 22.4% return
5Y
75%
of 369 industry peers · -17.7% return
Biotechnology peers with revenue growth within 4pp of HRMY's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
HRMY Harmony Biosciences 22.2% 10.8x -2.9%22.4%-17.7% —
INCY Incyte 18.6% 60.0x 14.3%119.4%83.2% +101pp
LGND Ligand Pharmaceuticals 21.7% 114.0x 45.9%408.1%81.4% +99pp
VCEL Vericel 20.6% 88.9x 46.8%58.2%36.7% +54pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is HRMY's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology ← 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.Acadia P. 
Mkt Price33.02241.42135.0045.49164.8718.3690.25
Mkt Cap1.915.67.17.616.83.27.4
Rev LTM9894,7188651,7543,7021,2021,478
Op Inc LTM2191,134-16391910122171
FCF LTM3231,414-832271,03786275
FCF 3Y Avg2801,252-10634469096312
CFO LTM3231,692-822431,06698283
CFO 3Y Avg2811,416-105380726166330

Growth & Margins

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.Acadia P. 
Rev Chg LTM19.8%13.5%54.2%15.3%38.0%14.8%17.5%
Rev Chg 3Y Avg22.2%7.6%57.2%3.7%27.8%24.9%23.6%
Rev Chg Q12.3%10.4%51.9%21.8%41.2%22.8%22.3%
QoQ Delta Rev Chg LTM3.1%2.5%11.4%5.2%9.7%5.6%5.4%
Op Inc Chg LTM-2.8%149.9%16.1%-74.6%64.4%29.6%22.9%
Op Inc Chg 3Y Avg4.6%45.3%1.0%-31.4%42.5%62.1%23.6%
Op Mgn LTM22.2%24.0%-18.9%5.2%24.6%10.2%16.2%
Op Mgn 3Y Avg25.1%17.3%-42.1%16.5%23.8%10.4%16.9%
QoQ Delta Op Mgn LTM-1.9%4.6%4.7%-3.4%0.7%2.6%1.6%
CFO/Rev LTM32.7%35.9%-9.5%13.9%28.8%8.1%21.3%
CFO/Rev 3Y Avg33.7%32.8%-22.2%24.4%24.6%16.3%24.5%
FCF/Rev LTM32.6%30.0%-9.5%13.0%28.0%7.2%20.5%
FCF/Rev 3Y Avg33.6%29.1%-22.3%22.1%23.3%9.7%22.7%

Valuation

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.Acadia P. 
Mkt Cap1.915.67.17.616.83.27.4
P/S1.93.38.24.44.52.63.8
P/Op Inc8.813.8-43.383.718.425.916.1
P/EBIT7.836.5-46.978.020.825.923.3
P/E10.875.8-45.0-21,756.423.88.79.8
P/CFO6.09.2-86.631.415.732.512.5
Total Yield9.3%1.3%-2.2%-0.0%4.2%11.5%2.7%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg14.2%13.7%-1.9%6.7%5.1%3.5%5.9%
D/E0.10.40.00.20.00.00.1
Net D/E-0.30.2-0.00.1-0.0-0.3-0.0

Returns

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.Acadia P. 
1M Rtn-13.0%14.8%-14.1%10.4%21.5%-4.0%3.2%
3M Rtn-14.9%-4.6%-37.4%-8.1%6.9%-39.2%-11.5%
6M Rtn8.5%1.7%-40.4%22.9%6.8%-10.4%4.2%
12M Rtn-2.8%41.9%-7.3%55.1%14.8%-23.5%6.0%
3Y Rtn22.5%100.2%125.5%87.7%51.3%-19.6%69.5%
1M Excs Rtn-8.5%19.4%-9.8%9.4%23.9%-3.7%2.9%
3M Excs Rtn-13.5%-0.5%-34.4%-5.6%9.8%-35.4%-9.5%
6M Excs Rtn7.6%0.8%-41.3%22.1%6.0%-11.2%3.4%
12M Excs Rtn-13.1%61.0%-13.4%46.5%3.7%-33.7%-4.7%
3Y Excs Rtn-29.1%32.7%67.6%37.6%-13.7%-85.4%9.5%

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA211150  WAKIXpitolisant hydrochloridetablet8142019     
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA211150  WAKIXpitolisant hydrochloridetablet8142019     

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Net product revenue868715582438305
Total868715582438305


Price Behavior

Price Behavior
Market Price$33.01 
Market Cap ($ Bil)1.9 
First Trading Date08/19/2020 
Distance from 52W High-23.0% 
   50 Days200 Days
DMA Price$38.28$34.53
DMA Trenddownindeterminate
Distance from DMA-13.8%-4.4%
 3M1YR
Volatility36.4%40.6%
Downside Capture136.3480.76
Upside Capture62.7867.90
Correlation (S&P 500)33.4%22.9%
HRMY Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.000.721.140.390.540.69
Up Beta-1.23-1.451.090.780.640.52
Down Beta-0.88-0.290.30-0.16-0.020.51
Up Capture196%137%166%63%78%74%
Bmk +ve Days12182862130427
Stock +ve Days14254068132374
Down Capture179%129%110%25%65%98%
Bmk -ve Days10253664121325
Stock -ve Days8182457115368

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HRMY
HRMY-3.0%40.6%0.02-
Sector ETF (XLV)24.2%16.9%1.1021.4%
Equity (SPY)10.2%13.8%0.4521.6%
Gold (GLD)-6.3%28.8%-0.23-2.0%
Commodities (DBC)31.6%21.3%1.18-8.4%
Real Estate (VNQ)10.0%14.2%0.425.5%
Bitcoin (BTCUSD)-31.4%43.7%-0.759.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HRMY
HRMY-4.8%49.4%0.08-
Sector ETF (XLV)8.6%15.4%0.3627.4%
Equity (SPY)10.9%17.3%0.4627.4%
Gold (GLD)15.5%19.2%0.65-2.2%
Commodities (DBC)7.1%19.6%0.25-1.6%
Real Estate (VNQ)0.9%19.0%-0.0624.2%
Bitcoin (BTCUSD)-0.6%51.4%0.1715.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HRMY
HRMY-1.1%51.6%0.16-
Sector ETF (XLV)12.4%16.8%0.6125.9%
Equity (SPY)14.9%18.0%0.7026.4%
Gold (GLD)11.2%16.6%0.55-2.3%
Commodities (DBC)7.4%18.2%0.320.5%
Real Estate (VNQ)5.8%20.7%0.2422.1%
Bitcoin (BTCUSD)57.2%66.3%0.9711.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity6.7 Mil
Short Interest: % Change Since 1015202623.1%
Average Daily Volume1.2 Mil
Days-to-Cover Short Interest5.6 days
Basic Shares Quantity58.4 Mil
Short % of Basic Shares11.4%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-7.0%-9.4% 
8/4/20268.9%9.6%15.9%
5/7/2026-4.1%-5.9%-1.8%
2/24/20264.9%7.6%0.9%
11/4/20254.7%8.5%30.4%
8/5/2025-1.7%-2.1%5.6%
5/6/20257.0%19.0%17.4%
2/25/20258.2%-5.9%-3.5%
...
SUMMARY STATS   
# Positive151514
# Negative101010
Median Positive6.2%9.6%16.2%
Median Negative-4.4%-6.8%-4.3%
Max Positive19.4%26.5%49.2%
Max Negative-17.6%-25.6%-12.0%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-7.0%-9.4% 
8/4/20268.9%9.6%15.9%
5/7/2026-4.1%-5.9%-1.8%
2/24/20264.9%7.6%0.9%
11/4/20254.7%8.5%30.4%
8/5/2025-1.7%-2.1%5.6%
5/6/20257.0%19.0%17.4%
2/25/20258.2%-5.9%-3.5%
10/29/202416.1%-7.6%-2.6%
8/6/20246.2%8.1%16.6%
4/30/20245.7%5.6%0.3%
2/22/2024-4.7%0.8%1.7%
10/31/202319.4%26.5%49.2%
8/1/2023-3.9%-5.3%-1.1%
5/2/20232.4%10.0%5.6%
2/21/2023-11.1%-9.2%-10.7%
11/1/202214.0%9.8%14.9%
8/2/202212.6%9.7%-10.3%
5/3/2022-17.6%-25.6%-5.1%
2/28/20225.4%6.1%34.4%
11/9/2021-0.9%-3.7%-7.0%
8/11/20214.1%3.4%18.9%
5/11/2021-3.1%11.5%22.3%
3/25/20213.5%14.9%-2.1%
11/12/2020-7.4%-9.8%-12.0%
SUMMARY STATS   
# Positive151514
# Negative101010
Median Positive6.2%9.6%16.2%
Median Negative-4.4%-6.8%-4.3%
Max Positive19.4%26.5%49.2%
Max Negative-17.6%-25.6%-12.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/04/202610-Q
03/31/202605/07/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/25/202510-K
09/30/202410/29/202410-Q
06/30/202408/06/202410-Q
03/31/202404/30/202410-Q
12/31/202302/22/202410-K
09/30/202310/31/202310-Q
06/30/202308/01/202310-Q
03/31/202305/02/202310-Q
12/31/202202/21/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/04/202610-Q
03/31/202605/07/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/25/202510-K
09/30/202410/29/202410-Q
06/30/202408/06/202410-Q
03/31/202404/30/202410-Q
12/31/202302/22/202410-K
09/30/202310/31/202310-Q
06/30/202308/01/202310-Q
03/31/202305/02/202310-Q
12/31/202202/21/202310-K
09/30/202211/01/202210-Q
06/30/202208/02/202210-Q
03/31/202205/03/202210-Q
12/31/202102/28/202210-K
09/30/202111/09/202110-Q
06/30/202108/10/202110-Q
03/31/202105/11/202110-Q
12/31/202003/25/202110-K
09/30/202011/12/202010-Q
06/30/202008/20/2020424B4
03/31/202007/27/2020S-1

Recent Forward Guidance

Updated 11/5/2026

Latest: Q3 2026 Earnings Reported 11/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 WAKIX Net RevenueReported1.00 Bil1.02 Bil1.04 Bil0.0% AffirmedGuidance: 1.02 Bil for 2026


Prior: Q2 2026 Earnings Reported 8/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 WAKIX Net RevenueReported1.00 Bil1.02 Bil1.04 Bil0 AffirmedGuidance: 1.02 Bil for 2026

Q1 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.00 Bil1.02 Bil1.04 Bil0.0% AffirmedGuidance: 1.02 Bil for 2026

Q4 2025 Earnings Reported 2/24/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.00 Bil1.02 Bil1.04 Bil19.3% Higher NewGuidance: 855.00 Mil for 2025

Insider Activity

Updated 9/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Budur, KumarCHIEF MEDICAL OFFICERDirectSell918202643.0535,8521,543,590564,660Form
2Budur, KumarCHIEF MEDICAL OFFICERDirectSell918202643.0080034,400563,945Form
3Budur, KumarCHIEF MEDICAL OFFICERDirectSell918202643.011,80077,426564,136Form
4Budur, KumarCHIEF MEDICAL OFFICERDirectSell909202642.9628,4541,222,258563,362Form
5Budur, KumarCHIEF MEDICAL OFFICERDirectSell909202641.985,500230,911781,530Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Budur, KumarCHIEF MEDICAL OFFICERDirectSell918202643.0535,8521,543,590564,660Form
2Budur, KumarCHIEF MEDICAL OFFICERDirectSell918202643.0080034,400563,945Form
3Budur, KumarCHIEF MEDICAL OFFICERDirectSell918202643.011,80077,426564,136Form
4Budur, KumarCHIEF MEDICAL OFFICERDirectSell909202642.9628,4541,222,258563,362Form
5Budur, KumarCHIEF MEDICAL OFFICERDirectSell909202641.985,500230,911781,530Form
6Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell128202637.153,746139,171911,004Form
7Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell120202635.9220,961  Form
8Dayno, Jeffrey MPRESIDENT, CEODirectSell1217202540.1125,933  Form
9Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell1209202539.5420,000  Form
10Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell1125202535.003,427  Form

Investor Activity (13F)

Updated Nov 18, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
venBio Partners LLC$13.7 Mil4.9%6Hold13F
Active Manager
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
venBio Partners LLC$13.7 Mil4.9%6Hold13F
Core Cache Last Updated: 11/17/2026